Sigyn Therapeutics, Inc. (OTCQB: SIGY) disclosed today that a recent study published in Science Translational Medicine and highlighted by Scientific American provides clinical evidence of blood-brain barrier disruption and chronic inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE). The findings support the potential use of the company's CardioDialysis blood purification technology to treat neuroinflammatory diseases.
On March 21, Scientific American published an article titled “Brain’s Protective Barrier Stays Leaky for Years after Playing Contact Sports,” coinciding with the release of a study from researchers at Trinity College Dublin. The study reported that the blood-brain barrier may remain compromised and permeable for decades after an athlete's retirement from sports involving repetitive head trauma. When the blood-brain barrier is compromised, inflammatory molecules and pathogenic toxins in the bloodstream can enter the brain, leading to neuroinflammation and the abnormal accumulation of tau protein, a hallmark of CTE. The researchers observed that former athletes in the study appeared to exist in a persistent state of chronic hyperinflammation.
The Trinity study adds to evidence that systemic inflammation is a key driver of neuroinflammation associated with disorders such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. CardioDialysis, a next-generation blood purification technology that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, is uniquely positioned to emerge as a potential adjunct therapy for these conditions. The company is pursuing a strategic transaction focused on reducing systemic inflammation associated with traumatic brain injury (TBI), while its lead clinical indication remains cardiovascular disease.
“It is becoming increasingly clear that CardioDialysis may play a meaningful role to slow the progression of neuroinflammatory disorders, particularly in high-risk individuals or during the early stages of disease,” stated Sigyn Therapeutics CEO Jim Joyce. “The dual reduction of inflammatory and pathogenic factors from the bloodstream could help stabilize the blood-brain barrier, which would limit the leakage of harmful molecules into the brain.”
The Scientific American article can be accessed at https://www.scientificamerican.com/article/brains-protective-barrier-stays-leaky-for-years-after-playing-contact-sports/.
CardioDialysis is the first therapy to integrate plasma separation and therapeutic adsorption within a single device. Beyond cardiovascular disease, it is being explored for sepsis, life-threatening viral infections, and neurological disorders associated with systemic inflammation. Sigyn's development pipeline also includes ImmunePrep, ChemoPrep, and ChemoPure.
